These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 36889379)
1. Do Reimbursement Recommendations by the Canadian Agency for Drugs and Technology in Health Translate Into Coverage Decisions for Orphan Drugs in the Canadian Province of Ontario? Fontrier AM; Kanavos P Value Health; 2023 Jul; 26(7):1011-1021. PubMed ID: 36889379 [TBL] [Abstract][Full Text] [Related]
2. Influencing Factors of Health Technology Assessment to Orphan Drugs: Empirical Evidence in England, Scotland, Canada, and Australia. Zhou N; Ji H; Li Z; Hu J; Xie JH; Feng YH; Yuan N Front Public Health; 2022; 10():861067. PubMed ID: 35784205 [TBL] [Abstract][Full Text] [Related]
3. Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada. Rawson NSB; Stewart DJ Clinicoecon Outcomes Res; 2024; 16():437-445. PubMed ID: 38812711 [TBL] [Abstract][Full Text] [Related]
4. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand. McCormick JI; Berescu LD; Tadros N Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371 [TBL] [Abstract][Full Text] [Related]
5. An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries. Ward LM; Chambers A; Mechichi E; Wong-Rieger D; Campbell C Orphanet J Rare Dis; 2022 Mar; 17(1):113. PubMed ID: 35246200 [TBL] [Abstract][Full Text] [Related]
6. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits? Rawson NSB Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235 [TBL] [Abstract][Full Text] [Related]
7. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries. Nicod E Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758 [TBL] [Abstract][Full Text] [Related]
8. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations. Fontrier AM Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552 [TBL] [Abstract][Full Text] [Related]
9. Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review. Balijepalli C; Gullapalli L; Druyts E; Yan K; Desai K; Barakat S; Locklin J Clinicoecon Outcomes Res; 2020; 12():445-457. PubMed ID: 32922050 [TBL] [Abstract][Full Text] [Related]
10. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe. Malinowski KP; Kawalec P; Trąbka W; Sowada C; Petrova G; Manova M; Savova A; Draganić P; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS Orphanet J Rare Dis; 2020 Oct; 15(1):277. PubMed ID: 33032634 [TBL] [Abstract][Full Text] [Related]
11. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access? Rawson NSB J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580 [TBL] [Abstract][Full Text] [Related]
12. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland. Allen N; Walker SR; Liberti L; Salek S Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476 [TBL] [Abstract][Full Text] [Related]
13. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review. Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281 [TBL] [Abstract][Full Text] [Related]
14. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe. Kawalec P; Sagan A; Pilc A Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717 [TBL] [Abstract][Full Text] [Related]
15. 'The problem is small enough, the problem is big enough': a qualitative study of health technology assessment and public policy on drug funding decisions for children. Denburg AE; Giacomini M; Ungar WJ; Abelson J Int J Equity Health; 2020 Mar; 19(1):45. PubMed ID: 32228588 [TBL] [Abstract][Full Text] [Related]
16. HTA decision-making for drugs for rare diseases: comparison of processes across countries. Stafinski T; Glennie J; Young A; Menon D Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398 [TBL] [Abstract][Full Text] [Related]
17. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study. Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843 [TBL] [Abstract][Full Text] [Related]
18. Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada. Nagase FNI; Stafinski T; Sun J; Jhangri G; Menon D Orphanet J Rare Dis; 2019 Jun; 14(1):127. PubMed ID: 31174574 [TBL] [Abstract][Full Text] [Related]
19. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries. Zelei T; Molnár MJ; Szegedi M; Kaló Z Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284 [TBL] [Abstract][Full Text] [Related]
20. Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations. Binder L; Ghadban M; Sit C; Barnard K Curr Oncol; 2022 Mar; 29(3):1514-1526. PubMed ID: 35323327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]